SPY002-072
Phase 2Small molecule
SPY002-072 is one of 58 small molecule programs targeting Rheumatic Disease. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
63 competitors in Rheumatic Disease
#DrugCompanyPhaseTrials
1Aleve
Jazz PharmaceuticalsApproved
Voltaren
NovartisApproved
Advil
KKenvue Brands
Approved
Decadron
AAspen Global Incorporated
Approved
Clinoril
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Zovirax
BBp Consulting, Inc
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Ansaid
PPharmacia and Upjohn
Approved
Bextra
TThe Searle Company Limited Pakistan
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SPY002-072. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSpyre Therapeutics, Inc.